Wells Fargo & Company MN Raises Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Wells Fargo & Company MN lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 53.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 104,163 shares of the biotechnology company’s stock after acquiring an additional 36,166 shares during the period. Wells Fargo & Company MN’s holdings in BioCryst Pharmaceuticals were worth $783,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of BCRX. Vanguard Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after purchasing an additional 1,583,826 shares during the last quarter. Hillsdale Investment Management Inc. raised its position in shares of BioCryst Pharmaceuticals by 65,213.3% in the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company’s stock valued at $4,077,000 after purchasing an additional 541,270 shares during the last quarter. Norges Bank purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $3,947,000. Schroder Investment Management Group raised its position in shares of BioCryst Pharmaceuticals by 523.9% in the 4th quarter. Schroder Investment Management Group now owns 522,657 shares of the biotechnology company’s stock valued at $3,936,000 after purchasing an additional 438,887 shares during the last quarter. Finally, Principal Financial Group Inc. raised its position in shares of BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares during the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday. They issued an “overweight” rating and a $20.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. Evercore ISI increased their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $11.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.13.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $8.85 on Thursday. The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -14.51 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.15 and a 12 month high of $9.50. The firm’s 50 day simple moving average is $7.67 and its 200-day simple moving average is $7.78.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.28 earnings per share. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.